Figs Inc. (FIGS)
NYSE NYSE Primary 
FIGS Shows Significant U.S. Weakness But Continues To Trade At 50x NOPAT
FIGS, Inc.'s earnings show mixed results, with strong international growth but declining U.S. sales and weak FY25 guidance, raising concerns about profitability and customer acquisition. Despite strong product innovation, FIGS struggles with high marketing costs, poor customer acquisition, and stagnating U.S. sales, making its high valuation unjustifiable. International expansion is promising but comes with lower margins; new management might improve execution, but significant challenges remain.
Figs (FIGS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Figs (FIGS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
FIGS, Inc. (FIGS) Q4 2024 Earnings Call Transcript
FIGS, Inc. (NYSE:FIGS ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Tom Shaw - Senior Vice President, Investor Relations Trina Spear - Co-Founder & Chief Executive Officer Sarah Oughtred - Chief Financial Officer Conference Call Participants Brooke Roach - Goldman Sachs Brian Nagel - Oppenheimer John Kernan - TD Cowen Dana Telsey - Telsey Group Lorraine Hutchinson - Bank of America Matt Koranda - ROTH Capital Ashley Owens - KeyBanc Capital Markets Nathan Feather - Morgan Stanley Operator Good afternoon, everyone, and thank you for joining today's FIGS Fourth Quarter Fiscal 2024 Earnings Conference Call. My name is Reagan, and I'll be your moderator today.
Figs (FIGS) Q4 Earnings Meet Estimates
Figs (FIGS) came out with quarterly earnings of $0.01 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.05 per share a year ago.
Countdown to Figs (FIGS) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Beyond analysts' top -and-bottom-line estimates for Figs (FIGS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Scrubs maker Figs rebuffs Story3 Capital's take-private offer
Figs said on Thursday it has rebuffed private equity firm Story3 Capital Partners' offer to acquire the scrubs maker.
Figs stock price sits in a range: will it have a breakout in 2025?
Figs stock has lost momentum and remained in a consolidation phase in almost two years. It remained inside the support and resistance levels at $4.42 and $6.97 in this period, missing the strong stock surge in the United States.
FIGS: Opportunistic Bid Grossly Undervalues A Recession Proof Business
An opportunistic offer by a PE fund during a 'retail lull' grossly undervalues FIGS, thus providing a chance for value and arbitrage investors to profit from the situation. Founded by Heather Hasson and Trina Spear, the stock has dropped from over $35 to $6.07 since its 2021 IPO and subsequent takeover offer. Story3 Capital's $6 per share offer to take the company private undervalues the business, which has strong free cash flow and no debt.
Is Figs a Buy After $1 Billion Buyout Rumors?
Shares of Figs (FIGS -3.85%) jumped this week after the company reportedly received a buyout offer for around $1 billion. In this video, Travis Hoium shows why private equity buyers may be interested and what the stock could do now.
Medical-Apparel Maker Figs Gets Takeover Bid From Private-Equity Firm
The Story3 proposal values the company at more than $1 billion.
Medical-Apparel Maker Figs Gets Takeover Bid From Private-Equity Firm
The Story3 proposal values the company at more than $1 billion.
FIGS Back To Q1 Prices, But The Name Is Still A Hold
Figs reported disappointing 3Q24 results with a 2% revenue decline and a 13 percentage point drop in adjusted EBITDA margins, leading to a 30% stock price drop. The company's high SG&A expenses and lack of growth make it difficult to compete against lower-priced alternatives, justifying my Hold rating. Questionable $25 million investment in a pre-product healthcare education app raises concerns about capital allocation and potential conflicts of interest.
